BioStem Technologies Announces $3 Million Private Placement

POMPANO BEACH, Fla., Sept. 30, 2026 /CourierPR/ -- BioStem Technologies Inc., a leading regenerative medicine company, has announced a $3 million private placement priced at-the-market under Nasdaq rules. The company plans to issue and sell 735,296 shares of its common stock, along with Series A and Series B warrants to purchase up to an aggregate of 735,296 shares of common stock. The shares will be sold at a purchase price of $4.08 each, and the warrants will have an exercise price of $3.83 per share and will be exercisable immediately upon issuance.

According to the terms of the offering, the aggregate gross proceeds to the company from the sale of the shares are expected to be approximately $3 million, before deducting placement agent fees and other offering expenses. If the warrants are exercised in full for cash, the company would receive additional gross proceeds of approximately $5.6 million. However, there can be no assurance that any of the warrants will be exercised.

The company intends to use the net proceeds from the offering for working capital and general corporate purposes. The securities described in the offering are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”) and Regulation D promulgated thereunder. The shares of common stock underlying the warrants sold in the offering, as well as the warrants themselves, have not been registered under the Act or applicable state securities laws. Accordingly, such securities may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements.

Pursuant to a registration rights agreement, the company has agreed to file one or more registration statements with the SEC covering the resale of the shares of common stock to be issued in the offering and issuable upon exercise of the warrants to be issued in the offering. The offering is expected to close on or about September 30, 2026, subject to the satisfaction of customary closing conditions.

BioStem Technologies, Inc. is a publicly traded, biomedical innovator focused on developing, manufacturing, and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain®, CryoTek®, and SteriTek® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties.

The company's quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (AATB). These systems and procedures are established in compliance with current Good Tissue Practices (cGTP) and current Good Manufacturing Practices (cGMP). BioStem’s portfolio of quality brands includes its Neox®, Clarix®, VENDAJE®, and American Amnion™ product lines.

Forward-looking statements in this press release include, without limitation, statements regarding the completion of the offering, the satisfaction of customary closing conditions related to the offering, the potential exercise of the warrants, and the intended use of net proceeds from the offering. These statements are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements.